With its focus on technology, Kennedy van der Laan of course also has a Life Sciences team, which can assist you with its knowledge of the market. In this international and complex environment, in which both technology and regulations play a big role, we will be pleased to help you find the appropriate strategy and tailor-made legal solutions.
Our team is working for investors in life sciences, for start-up companies and established companies in this field, and for various public and semi-public institutions looking for cooperation with the business sector. Our financing specialists advise in the field of private equity and venture capital financing. Our intellectual-property specialists have broad experience in drafting (international) cooperation and licensing contracts, taking action against infringement and solving disputes in complex R&D environments.
We have given advice to various biotechnology companies from the United States, amongst other things on the restructuring of activities in the Netherlands, the purchase of a Dutch biotechnology company and the sale of a subsidiary. We have assisted various start-up companies in the incorporation process and with the financing documentation. For an American not-for-profit organization we have negotiated the purchase of a patent portfolio and have litigated about the ownership of a registration file. For a Dutch government institution we have negotiated with various international partners about technology transfer and research cooperation. These are only a few examples of our law practice. If you would like to receive more detailed information about our experience and expertise, please do not hesitate to contact us.
Kennedy Van der Laan is an associate of Biolegis, a network of independent law firms with specific knowledge and experience in the field of biotechnology. See www.biolegis.com.
The reputable “Chambers Guides” has announced its nominations for the “Chambers Europe Law Firm of the Year Awards 2015″ and Kennedy Van der...11 march 2015
An interesting change that will perhaps be overlooked at first is the possibility to divide voting rights of shareholders. Such a division is...23 april 2013